|
||||||
In Business 32 Years - Since 1980 |
THE CURRENT TIME at LC Labs is: |
|||||
[GSK 572016] [GW-572016] [GW 572016X] [Tykerb] [Tyverb]
![]() |
![]() |
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
100 mg |
47 |
36 |
30 |
3600 |
| ||
|
200 mg |
77 |
58 |
49 |
5900 |
| ||
|
300 mg |
111 |
84 |
70 |
8500 |
| ||
|
500 mg |
148 |
112 |
94 |
11300 |
| ||
|
1 g |
247 |
188 |
156 |
18900 |
| ||
|
2 g |
465 |
353 |
294 |
35600 |
| ||
|
5 g |
990 |
752 |
626 |
75900 |
| ||
|
10 g |
1890 |
1436 |
1195 |
144900 |
| ||
|
25 g |
3690 |
2803 |
2332 |
282900 |
| ||
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
| Compare Quality and Prices LC Labs vs. Other Suppliers |
|---|
M.W. 581.06
C29H26ClFN4O4S
[231277-92-2]
M.I. 14: 5367
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 1-10 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A
Find and View a Certificate of Analysis for this product
View the MSDS for this product
This is the free base form of lapatinib; please see our product Lapatinib, Di-p-Toluenesulfonate Salt, Cat. No. L-4804, for further technical information. The di-p-toluenesulfonate salt form of lapatinib, not the free base, is used in the lapatinib formulation for use in humans.
Lapatinib (as the di-p-toluenesulfonate salt) is the active ingredient in the drug sold under the trade names Tykerb® in the US and Tyverb® in Europe. This drug has been approved in at least one country to treat advanced metastatic breast cancer in conjunction with the chemotherapy drug Xeloda (generic name, capecitabine).
The CAS number for Lapatinib, Free Base is given above. The CAS number of the di-p-toluenesulfonate salt (Cat. No. L-4804) is 388082-77-7.
Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
Not available in some countries; not available to some institutions; not available for some uses.
Our products are for laboratory research only and are sold only to qualified research institutions, not to individuals or patients nor for veterinary use.